Anti-infective Agents Market Size & Growth Forecast 2027–2036, By Segments (Distribution Channel, Type, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Anti-infective Agents Market size was more than USD 132.9 billion in 2026 and is set to grow at a 1.9% CAGR between 2027 and 2036, reaching USD 160.42 billion by 2036. The industry revenue for 2027 is estimated at USD 135.03 billion.
Get more details on this report
Request Free Sample ReportAnti-infective Agents Market Intelligence Snapshot
Regional Market Dynamics
- North America holds 40.39% share due to established treatment systems, broad prescription access, and consistent use across hospitals, outpatient care, and long-term care settings.
- Asia Pacific grows at 1.94% CAGR, driven by expanding healthcare access, rising patient treatment uptake, and broader availability of essential anti-infective therapies.
Segment Momentum
- Hospital Pharmacies held a 51.41% market share in 2026, driven by their central role in dispensing injectable therapies, supporting inpatient treatment, and managing physician-directed infection care.
- Antifungals are the fastest-growing type segment as demand rises for targeted treatment of serious fungal infections, particularly among vulnerable patient groups requiring timely and effective therapy.
Market Expansion Drivers
- Rising global infectious disease burden increasing demand for targeted antimicrobial therapies.
- Government-funded R&D programs accelerating development of novel antiviral and antibacterial drugs.
- Growth of antimicrobial resistance driving innovation in next-generation therapeutic solutions.
Leading Market Participants
- Major companies in the anti-infective agents market include Pfizer Inc. (United States), Bayer AG (Germany), AbbVie Inc. (United States), Gilead Sciences, Inc. (United States), Bristol-Myers Squibb Company (United States), Merck & Co., Inc. (United States), Johnson & Johnson (United States), AstraZeneca plc (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Sandoz Group AG (Switzerland).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 132.9 billion
- 2027 Estimated Market Size: USD 135.03 billion.
- Projected Market Size: USD 160.42 billion by 2036
- Growth Forecast: 1.9% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Hospital Pharmacies (Distribution Channel) | Antivirals (Type) | Oral (Route of Administration)
- Emerging Opportunity Segment: Retail Pharmacies (Distribution Channel) | Antifungals (Type) | Parenteral (Route of Administration)
Market Growth Drivers and Industry Trends
Rising global infectious disease burden increasing demand for targeted antimicrobial therapies
The continuing burden of bacterial, viral, fungal, and other infectious diseases will drive the anti-infective agents market growth by sustaining the need for therapies that can address a broad range of pathogens. Population mobility, healthcare-associated infections, and changing disease patterns can increase the complexity of infection management and reinforce demand for effective treatment options. Greater emphasis on pathogen-specific diagnosis is also supporting the use of targeted therapies that can be selected according to the underlying infectious agent and clinical condition.
Government-funded R&D programs accelerating development of novel antiviral and antibacterial drugs
Public investment in infectious disease research will propel the anti-infective agents market by helping researchers and drug developers advance new antiviral and antibacterial candidates through discovery and development stages. Government-supported initiatives can provide funding for early-stage research, clinical development, and innovation addressing pathogens where commercial investment may otherwise be limited. Such programs also strengthen collaboration among research institutions, healthcare organizations, and pharmaceutical developers working on new mechanisms of action and treatment approaches.
Growth of antimicrobial resistance driving innovation in next-generation therapeutic solutions
Increasing antimicrobial resistance is strengthening the anti-infective agents market by creating an urgent need for treatments capable of addressing pathogens that no longer respond adequately to existing therapies. Resistant infections can complicate treatment decisions and increase pressure on healthcare systems to identify alternative mechanisms, combination therapies, and more targeted antimicrobial approaches. Drug discovery efforts are therefore increasingly focused on overcoming resistance mechanisms and developing therapeutic options that can retain activity against difficult-to-treat infections.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global infectious disease burden increasing demand for targeted antimicrobial therapies | 2.30% | High | North America, Asia Pacific | High | Near Term |
| Government-funded R&D programs accelerating development of novel antiviral and antibacterial drugs | 2.00% | High | Europe, North America | High | Mid Term |
| Growth of antimicrobial resistance driving innovation in next-generation therapeutic solutions | 1.70% | High | Asia Pacific, Europe | Medium | Mid Term |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America dominated the anti-infective agents market with a 40.39% share in 2026, reflecting strong healthcare infrastructure, high utilization of advanced therapeutic products, and continued investment in infectious disease management. The region benefits from established diagnostic capabilities that support timely identification and treatment of bacterial, viral, fungal, and other infectious conditions. Rising healthcare expenditure, increasing awareness of antimicrobial resistance, and the need for effective therapies against complex infections are also reinforcing demand for anti-infective agents.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to represent the fastest-growing regional market, supported by expanding healthcare access, growing patient populations, and increasing prevalence of infectious diseases in several countries. Improvements in hospital infrastructure, wider availability of diagnostic services, and greater public and institutional emphasis on infection prevention are encouraging broader adoption of anti-infective therapies. In addition, expanding pharmaceutical manufacturing and healthcare investment are strengthening the region's capacity to meet rising demand for infectious disease treatments.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Hospital Stewardship IntegrationGermany strengthens the anti-infective agents market through structured antimicrobial stewardship programs across hospitals and specialized care settings. German healthcare institutions increasingly adopt evidence-based prescribing practices while supporting demand for effective therapies against resistant pathogens.
France 🇫🇷
Public Health PreparednessFrance supports the anti-infective agents market through coordinated public health initiatives focused on infectious disease management and antimicrobial stewardship. Healthcare providers increasingly prioritize therapies that balance treatment effectiveness with responsible prescribing practices.
Italy 🇮🇹
Clinical Care OptimizationItaly emphasizes optimized anti-infective therapy selection across hospitals to improve patient outcomes and address evolving resistance patterns. Italian healthcare providers increasingly integrate stewardship initiatives with diagnostic capabilities to support appropriate antimicrobial use.
Japan 🇯🇵
Precision Infection ManagementJapan focuses on precision infection management by combining advanced diagnostics with carefully selected anti-infective therapies. The Japanese market emphasizes optimized treatment pathways, hospital infection control, and products that support appropriate antimicrobial utilization.
South Korea 🇰🇷
Rapid Treatment AdoptionSouth Korea advances the anti-infective agents market through rapid adoption of innovative therapies within technologically advanced healthcare systems. Clinical priorities include effective management of resistant infections, improved diagnostic integration, and efficient treatment protocols.
United States 🇺🇸
Antimicrobial Innovation PipelineThe U.S. anti-infective agents market prioritizes the development of novel therapies addressing antimicrobial resistance and complex infectious diseases. Healthcare providers increasingly emphasize targeted treatments, stewardship programs, and rapid diagnostics to optimize clinical outcomes and responsible antimicrobial use.
Segment Leadership and Growth Trends
Anti-infective Agents Market Share (%), by Distribution Channel, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportDistribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Retail Pharmacies (Fastest-Growing Segment)
The hospital pharmacies segment dominated the anti-infective agents market, accounting for a 51.41% share in 2026, due to the high volume of anti-infective treatments administered in hospital settings for acute, severe, and complex infections. Hospitals require reliable access to a broad range of antibacterial, antiviral, antifungal, and other anti-infective therapies to support inpatient care and timely treatment decisions. The presence of specialized physicians, diagnostic capabilities, and antimicrobial stewardship programs further supports procurement through hospital pharmacies. Rising demand for intensive infection management and the need for close monitoring of patients receiving advanced therapies continue to reinforce the segment's leading position.
The retail pharmacies segment is expected to grow the fastest, supported by increasing access to prescription anti-infective medicines for patients receiving treatment outside hospital settings. The expansion of community-based healthcare, greater availability of chronic infection management therapies, and growing consumer preference for convenient medication access are strengthening demand through retail channels. Retail pharmacies also play an important role in supporting treatment continuity, prescription refills, and patient access to medicines for common infectious conditions. Ongoing expansion of pharmacy networks and improvements in medicine availability are expected to further support segment growth.
Type Segment Analysis: Antivirals (Largest Segment) vs Antifungals (Fastest-Growing Segment)
The antivirals segment held the largest share of the anti-infective agents market at 53.45% in 2026, driven by the substantial need for therapies used in the management of a wide range of viral infections. Continued demand for effective treatment options, particularly for persistent and severe viral diseases, supports the extensive use of antiviral agents across healthcare settings. Advances in antiviral drug development and the increasing focus on targeted therapies are also expanding treatment capabilities. Greater emphasis on early diagnosis and timely intervention, combined with ongoing public health efforts to manage viral disease burdens, continues to strengthen the segment's market position.
The antifungals segment is anticipated to register the fastest growth as healthcare providers face increasing demand for effective treatment of fungal infections, particularly among immunocompromised and critically ill patients. Rising awareness of invasive fungal diseases and improvements in diagnostic capabilities are supporting earlier identification and treatment. The growing complexity of fungal infections and concerns surrounding resistance are also encouraging the development and adoption of more effective therapeutic options. As the need for specialized infection management expands across hospitals and other care settings, demand for antifungal agents is expected to accelerate.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Others | Hospital Pharmacies | Retail Pharmacies |
| Type | Antibacterials, Antivirals, Antifungals | Antivirals | Antifungals |
| Route of Administration | Oral, Parenteral, Topical, Others | Oral | Parenteral |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Top players in the anti-infective agents market:
1. Pfizer Inc. (United States)
2. Bayer AG (Germany)
3. AbbVie Inc. (United States)
4. Gilead Sciences Inc. (United States)
5. Bristol-Myers Squibb Company (United States)
6. Merck & Co. Inc. (United States)
7. Johnson & Johnson (United States)
8. AstraZeneca plc (United Kingdom)
9. Boehringer Ingelheim International GmbH (Germany)
10. Sandoz Group AG (Switzerland)
The anti-infective agents market is evolving with continuous development of next-generation therapies designed to combat resistant pathogens and emerging infections. Strong research focus is enabling improved efficacy and broader therapeutic coverage. The anti-infective agents market is increasingly driven by innovation in infectious disease treatment strategies.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. (United States) | |||||||
| Bayer AG (Germany) | |||||||
| AbbVie Inc. (United States) | |||||||
| Gilead Sciences Inc. (United States) | |||||||
| Bristol-Myers Squibb Company (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| Johnson & Johnson (United States) | |||||||
| AstraZeneca plc (United Kingdom) | |||||||
| Boehringer Ingelheim International GmbH (Germany) | |||||||
| Sandoz Group AG (Switzerland). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Shionogi & Co. | Aug-24 | Shionogi submitted a New Drug Application (NDA) for cefiderocol, a novel siderophore cephalosporin, to China's Center for Drug Evaluation. Cefiderocol, which targets multidrug-resistant Gram-negative bacteria, has demonstrated superior clinical efficacy in Phase III trials and is currently supporting the company’s broader strategic objective to expand global access to advanced antimicrobial treatments. |
| Sandoz | Mar-24 | Sandoz inaugurated a new antibiotic production facility in Kundl, Austria, following a EUR 50 million investment. This expansion increases finished dosage form capacity by 20% to 240 million packages annually, significantly scaling the production of penicillin and pediatric formulations to address global supply shortages and bolster European manufacturing resilience. |
| Basilea Pharmaceutica | Jan-24 | Basilea Pharmaceutica acquired a preclinical antibiotic program from Spexis AG, focused on novel LptA-inhibitors that disrupt Gram-negative bacterial lipopolysaccharide transport. This acquisition strengthens the company’s R&D pipeline against high-priority multidrug-resistant pathogens, strategically expanding its anti-infective portfolio to address unmet medical needs in hospital-based infection management. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Anti-infective Agents Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Indication | Respiratory Infections, Urinary Tract Infections, Skin & Soft Tissue Infections, Gastrointestinal Infections, Sexually Transmitted Infections, Systemic & Other Infections |
| Prescription Status | Prescription Agents, Over-the-Counter Agents |
| End User | Hospitals, Clinics & Physician Offices, Home Healthcare, Other Healthcare Settings |
Anti-infective Agents Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Antimicrobial Stewardship Impact Assessment |
|
| Infectious Disease Burden and Treatment Gap Analysis |
|
| Pathogen Resistance Hotspot Mapping |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the anti-infective agents market?
What are the growth projections for the anti-infective agents industry?
How is antimicrobial resistance reshaping innovation priorities in the anti-infective agents market?
What role do government-funded R&D programs play in market expansion for anti-infective agents?
Why are Hospital Pharmacies the leading distribution channel in the anti-infective agents market?
Which type segment is expanding the fastest in the anti-infective agents market?
Why does North America dominate the anti-infective agents market?
How is Asia Pacific expanding the anti-infective agents market?
Who are the leading players in the anti-infective agents landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization